Coronaios: Pfizer vaccine “90% effective”



The Covid-19 vaccine being developed by Pfizer and Biontech reduces the risk of infection by 90%, the two laboratories announced today, citing preliminary results in the third phase of clinical trials, the last step before marketing. The efficacy of the vaccine was measured by comparing the number of participants infected with the new coronavirus in the vaccine group and in the placebo group, “seven days after the second dose” and 28 days after the first, the two explained. If approved by the US Food and Drug Administration (FDA), the Pfizer vaccine will be one of the first mRNA vaccines to hit the market. According to the announcement, the Independent Data Monitoring Committee (DMC) analyzed Preliminary Findings “” has not reported serious safety concerns and recommends that the additional efficiency and safety data. The data will be made available to regulators worldwide. ”Pfizer, which has marketed the vaccine developed by Biontech, expects production to reach 50 million doses of the vaccine by 2020 and 1.3 billions in 2021. “Today is a great day for science and humanity,” said Dr. Albert Burla, President and CEO of Pfizer. “We are reaching this crucial milestone […,] “At a time when people need it the most, as coronavirus cases hit a new record, hospitals are nearing full capacity and economies are struggling to reopen,” he said. 39,000 have already received both required doses of the candidate vaccine, which is provisionally named BNT162b2. To date, 164 confirmed coronavirus cases have been reported among participants, selected to give a representative picture of the American population. in the



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *